Ovid Therapeutics (OVID) Net Income towards Common Stockholders Growth (1y) (2017 - 2026)
Powered by 
Analysis
Ovid Therapeutics (OVID) Net Income towards Common Stockholders Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -0.05% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 284.27% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -130.19% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -19.23% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | -108.13% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 151.28% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 44.59% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | -220.43% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -220.43% |
| Mar 31, 2026 | -65.98% |
| Dec 31, 2025 | 204.43% |
| Sep 30, 2025 | 13.19% |
| Jun 30, 2025 | -154.97% |
| Mar 31, 2025 | 12.48% |
| Dec 31, 2024 | 39.61% |
| Sep 30, 2024 | -24.46% |
| Jun 30, 2024 | 168.67% |
| Mar 31, 2024 | 12.44% |
| Dec 31, 2023 | -33.18% |
| Sep 30, 2023 | 5.97% |
| Jun 30, 2023 | 14.95% |
| Mar 31, 2023 | 17.08% |
| Dec 31, 2022 | 55.75% |
| Sep 30, 2022 | -5.13% |
| Jun 30, 2022 | 7.60% |
| Mar 31, 2022 | -109.15% |
| Dec 31, 2021 | -18.02% |
| Sep 30, 2021 | 30.69% |